Cargando…
Comparative analysis and meta-analysis of major clinical trials with oral factor Xa inhibitors versus warfarin in atrial fibrillation
OBJECTIVES: A comparative analysis of three major clinical trials with factor Xa inhibitor oral anticoagulant (XOAC) drugs versus warfarin in atrial fibrillation—Rocket-AF (rivaroxaban), Aristotle (apixaban) and Engage AF Timi 48 (edoxaban; two different doses and sets of data)—was carried out. METH...
Autores principales: | Nunes, José Pedro L, Rodrigues, Rui Paulo, Gonçalves, Francisco Rocha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189339/ https://www.ncbi.nlm.nih.gov/pubmed/25332806 http://dx.doi.org/10.1136/openhrt-2014-000080 |
Ejemplares similares
-
Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis
por: Nochaiwong, Surapon, et al.
Publicado: (2016) -
Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021) -
Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta‐Analysis
por: Deng, Yuqing, et al.
Publicado: (2019) -
Prophylactic Atrial Fibrillation Ablation in Atrial Flutter Patients without Atrial Fibrillation: A Meta-Analysis with Trial Sequential Analysis
por: Xie, Xinxing, et al.
Publicado: (2018) -
Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis
por: Pan, Kuo‐Li, et al.
Publicado: (2017)